Delivery vehicle for recombinant proteins
View Patent ↗Recombinant nucleic acid molecules are constructed with a first sequence encoding a transgene under the control of regulatory sequences that direct expression of the transgene product in a hematopoietic stem cell, or a progenitor cell therefrom or cell differentiated therefrom. In one embodiment, the cell which expresses the transgene is a secretory cell. The cell is a megakaryotic progenitor cell, or a cell further differentiated therefrom, such as a platelet. The cell is a granulocyte/macrophage progenitor cell or a cell further differentiated therefrom, such as a mast cell or neutrophils. Such host cells containing the molecule or the molecule itself are employed in methods for treating or preventing infection, inflammation or vascular injuries or any disorders involving or mediated by cells of the hematopoietic lineage.
1. An isolated platelet transformed, transduced, infected or transfected with a nucleic acid molecule comprising a first sequence encoding the transgene urokinase-type plasminogen activator (uPA) under the control of the Platelet factor 4 (PF4) promoter that directs expression and storage of urokinase-type plasminogen activator in granules in said platelet.
2. A method for treating or preventing thrombus formation in a mammal comprising delivering to a mammalian patient a platelet according to claim 1 .
3. The method according to claim 2 , wherein the platelet produces said uPA at a suitable site in said mammal.
4. The method according to claim 2 , wherein said delivering comprises administering said platelet directly into the blood circulation of said mammal.